Related Experiment Video
Updated: Jun 5, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Personalizing Quality Improvement: Addressing Anticoagulation Gaps in Atrial Fibrillation
Insights
Many atrial fibrillation patients identified with anticoagulation gaps do not require treatment. A pharmacist-led review confirmed most apparent gaps were explained, highlighting potential overestimation in quality metrics.
Area of Science:
- Pharmacology
- Cardiology
- Health Services Research
Background:
- Atrial fibrillation significantly increases stroke risk.
- Anticoagulation therapy is effective but underutilized in eligible patients, indicating a care quality gap.
- A pharmacist-led quality improvement initiative aimed to address these anticoagulation treatment gaps.
Purpose of the Study:
- To identify, verify, and close apparent anticoagulation treatment gaps in patients with atrial fibrillation.
- To evaluate the accuracy of automated algorithms in detecting anticoagulation care gaps.
Main Methods:
- Adult primary care patients with atrial fibrillation and a CHA2DS2-VASc score of at least 2, without current anticoagulant use, were included.
- Patients were identified using claims and electronic health record data.
- Chart review and provider outreach were used to verify and explain apparent treatment gaps.
Main Results:
- Of 242 patients with apparent gaps, 84% had verified treatment gaps.
- However, 86% of verified gaps were explained by factors like spontaneous AF resolution, patient refusal, procedures, or high bleeding risk.
- Pharmacist review and provider outreach resolved most identified opportunities.
Conclusions:
- Automated algorithms relying solely on claims and EHR data can significantly overestimate anticoagulation care gaps.
- A thorough verification process is crucial for accurate assessment of quality metrics in anticoagulation management.
Introduction:
Risk of stroke is greater in patients with atrial fibrillation. Anticoagulation is effective at decreasing risk, yet 40-50% of eligible patients are not prescribed anticoagulation and seem to have a concerning gap in care quality. This quality improvement initiative implemented a pharmacist-led approach to identify, verify, and close apparent anticoagulation treatment gaps.
Methods:
We included adult primary care patients with diagnosis of atrial fibrillation; congestive heart failure, hypertension, age ≥75 years (doubled), diabetes, stroke/transient ischemic attack (doubled), vascular disease, age 65-74 years, and sex (female) (CHA 2 DS 2 -VASc) score of at least 2, and no current anticoagulant use. We identified patients using claims and electronic health record data and evaluated explanations through chart review and provider contact. A provider outreach protocol was developed and implemented to address opportunities for anticoagulation.
Results:
Of 242 patients with an apparent gap, 84% had a verified treatment gap. However, 86% of verified treatment gaps were explained through pharmacist chart review and outreach to providers, and they did not require further action. Explanations included spontaneous resolution of atrial fibrillation, patient declining treatment, completion of a procedure to correct atrial fibrillation or mitigate stroke risk, and high bleeding risk.
Conclusions:
Relying solely on claims- and electronic health record-based algorithms may substantially overestimate gaps in care quality.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Errors occurring during blood pressure monitoring
Several factors...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis

